Add time:08/28/2019         Source:sciencedirect.com

In a randomized, double-masked, placebo-controlled study, 0.25 μg (n = 11) or 0.5 μg (n = 13) of prostaglandin F2α-1-isopropyl ester (PGF2α-IE) was applied topically twice daily for 8 days to one eye of ocular hypertensive or chronic open-angle glaucoma patients. Compared with contralateral, vehicle-treated eyes, PGF2α-IE significantly (P < 0.05) reduced intraocular pressure (IOP), beginning 4 hours after the first 0.5-μg dose and lasting at least 12 hours after the fourteenth dose, with a significant (P < 0.005) mean reduction of 4 to 6 mmHg maintained throughout the last day of therapy with either dose. A contralateral effect was not observed. Mean tonographic outflow facility was significantly (P < 0.05) higher in PG-treated compared with vehicle-treated eyes (0.17 ± 0.02 versus 0.12 ± 0.01 μl/minute/mmHg, respectively; ± standard error of the mean) for the 0.5-μg dose. Conjunctival hyperemia reached a maximum at 30 to 60 minutes after PGF2α-IE application. Some patients reported mild irritation lasting several minutes after some doses. Visual acuity, accommodative amplitude, pupillary diameter, aqueous humor flare, anterior chamber cellular response, Schirmer's test, pulse rate, and blood pressure were not significantly altered. Our findings show that PGF2α-IE is a potent ocular hypotensive agent and a promising drug for glaucoma therapy.

We also recommend Trading Suppliers and Manufacturers of prostaglandin A2 isopropyl ester (cas 114084-85-4). Pls Click Website Link as below: cas 114084-85-4 suppliers